Synonyms: NMD-670
Compound class:
Synthetic organic
Comment: NMD670 is a ClC-1 voltage-sensitive chloride channel inhibitor [1]. It is intended to improve neuromuscular transmission, muscle fiber excitability and muscular function in diseases with underlying compromised transmission between motor neurons and skeletal muscle fibers (e.g. myasthenia gravis, spinal muscular atrophy).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
NMD670 was first evaluated in patients with myasthenia gravis [1], and is a current clinical candidate for spinal muscular atrophy. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05794139 | Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy | Phase 2 Interventional | NMD Pharma A/S |